TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

BELBUCA

BUPRENORPHINE HYDROCHLORIDE
Approved 2015-10-23
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2015-10-23
Routes
BUCCAL
Dosage Forms
FILM

Companies

Active Ingredient: BUPRENORPHINE HYDROCHLORIDE

BELBUCA Approval History

Loading approval history...

What BELBUCA Treats

1 indications

BELBUCA is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pain
Source: FDA Label

BELBUCA Boxed Warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF BELBUCA See full prescribing information for complete boxed warning. BELBUCA exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a ...

Drugs Similar to BELBUCA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Pain
BUPRENORPHINE
BUPRENORPHINE
1 shared
WATSON LABS TEVA
Shared indications:
Pain
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
ASPIRIN
1 shared
STEVENS J
Shared indications:
Pain
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE
1 shared
Hikma
Shared indications:
Pain
BUTORPHANOL TARTRATE PRESERVATIVE FREE
BUTORPHANOL TARTRATE
1 shared
Pfizer
Shared indications:
Pain
BUTRANS
BUPRENORPHINE
1 shared
PURDUE PHARMA LP
Shared indications:
Pain
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Pain
CALDOLOR
IBUPROFEN
1 shared
CUMBERLAND PHARMS
Shared indications:
Pain
CATAFLAM
DICLOFENAC POTASSIUM
1 shared
AMICI PHARMA
Shared indications:
Pain
COMBOGESIC IV
ACETAMINOPHEN
1 shared
Hikma
Shared indications:
Pain
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
1 shared
INGENUS PHARMS LLC
Shared indications:
Pain
DIFLUNISAL
DIFLUNISAL
1 shared
Teva
Shared indications:
Pain
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Pain
DILAUDID
HYDROMORPHONE HYDROCHLORIDE
1 shared
Fresenius Kabi
Shared indications:
Pain
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Pain
EC-NAPROSYN
NAPROXEN
1 shared
ATNAHS PHARMA US
Shared indications:
Pain
EXPAREL
BUPIVACAINE
1 shared
PACIRA PHARMS INC
Shared indications:
Pain
FLECTOR
DICLOFENAC EPOLAMINE
1 shared
IBSA
Shared indications:
Pain
GLYDO
LIDOCAINE HYDROCHLORIDE
1 shared
SAGENT PHARMS INC
Shared indications:
Pain
HYDROCODONE BITARTRATE AND ASPIRIN
ASPIRIN
1 shared
LGM PHARMA
Shared indications:
Pain
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BELBUCA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. BELBUCA buccal film contains buprenorphine, a partial opioid agonist. BELBUCA is indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or d...

⚠️ BOXED WARNING

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF BELBUCA See full prescribing information for complete boxed warning. BELBUCA exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patien...

BELBUCA Patents & Exclusivity

Latest Patent: Dec 2032

Patents (147 active)

US9901539 Expires Dec 21, 2032
US8147866 Expires Jul 23, 2027
US9655843 Expires Jul 23, 2027
+ 137 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.